🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excited to have contributed to this work with great collaborators IGNITE Network. We evaluated relative importance of implementation factors for PGx testing to guide antidepressants @sony_tuteja Ramzi Salloum UF Health Precision Medicine Laura Ramsey Philip Empey Ben Duong Natasha Petry

Mark your calendars and join us for journal club: Tuesday, June 7th from 8-9:15 pm EST Registration link for the session is: lnkd.in/gAFjMh5S Link to Articles: lnkd.in/gFQtEwye lnkd.in/g-XNzY7K

#Pharmacogenomics is the study of how genes affect medication responses. This knowledge can help clinicians make better decisions. Max Smith of MedStar Health Research and colleagues from @NorthShoreWeb published a review of #PGx clinical decision support tools. doi.org/10.1002/cpt.27…

Electronic clinical decision support (CDS) is commonly called for in #PGx implementations. We conducted a scoping review on the current state. Most literature was on interruptive alerts but had a wide variability in response Mark Dunnenberger ASCPT Journal Family doi.org/10.1002/cpt.27…

A great article for anyone wondering how to counsel patients on PGx testing or how others do it.

A successful large-scale #pharmacogenetics implementation requires coordination and synergy among administrators, clinicians, informatics teams, laboratories, and patients accpjournals.onlinelibrary.wiley.com/doi/10.1002/ja…

Recent collab with @WilliamFigg1 (National Cancer Institute) where we comment on a recent trial and describe the current evidence & resources for #opioid pharmacogenetics #PGx. National Comprehensive Cancer Network (NCCN) Adult Cancer Pain guidelines support PGx testing CPIC #TwitteRx PGRN pubmed.ncbi.nlm.nih.gov/36718020/

Happy to contribute to this work that calls upon the National Comprehensive Cancer Network (NCCN) U.S. FDA & ASCO to recommend DPYD testing when prescribing 5-FU and capecitabine. CPIC #PGx ascopubs.org/doi/full/10.12…

Key takeaway from the Precision Medicine Leaders Summit? The future is now. Precision Medicine Leaders Summit GenomeWeb UF Pharmacy Max Smith Jai Patel Sanford Health Atrium Health MedStar Health Texas A&M Pharmacy Texas A&M IBT Texas A&M Health

Happy to discuss the pharmacist's role in PGx implementation at the Precision Medicine Leaders Summit. UF Pharmacy GenomeWeb

Must read article on pharmacogenetics in cancer. DPYD Testing: Time to Put Patient Safety First. Call for National Comprehensive Cancer Network (NCCN) & ASCO guidelines to incorporate testing prior to treatment with fluoropyrimidines. ascopubs.org/doi/10.1200/JC… Gabriel Brooks howard mcleod Journal of Clinical Oncology

Happy to contribute to this work where we call upon the FDA to align with Europe in recommending DPYD testing and genotype-based dose adjustment to ensure patients with cancer receive safe and effective fluoropyrimidine chemotherapy Jai Patel et. al. ascpt.onlinelibrary.wiley.com/doi/abs/10.100…

We asked oncology providers in our health system about PGx. It is important to stratify based on whether they typically prescribe that drug (figure). Providers with previous PGx education were more likely to have ordered a test (OR: 7.9; 95% CI: 1.1–56) futuremedicine.com/doi/10.2217/pg…

Oncologists are interested in #Pharmacogenomics and believe it can improve cancer care! Read more in this Future Medicine (Future Science Group) paper from Beth Peshkin, marc schwartz, Nadia Ashai, Sandra, Max Smith, and colleagues. doi.org/10.2217/pgs-20… MedStar Health Research #PGx

Happy to present these data today and work with a great team Ilana Schlam Sandra Georgetown Cancer Prevention and Control Program

.Max Smith and colleagues assessed appraoches to pre-chemotherapy testing for dihydropyrimidine dehydrogenase deficiency (DPYD) in the US. Their take-away? Routine DPYD testing requires coordinated healthcare team effort. doi.org/10.1007/s00520… MedStar Health Research Supportive Care in Cancer: Springer Journal

New clinical trial results! Ribociclib is used to treat certain breast cancers. We knew CYP3A inhibitors increase ribo levels by 3-fold. But does CYP3A5 genotype predict ribociclib levels? In short, no. A reassuring result for patients and clinicians. Georgetown Cancer Prevention and Control Program PGRN

Congrats to Max Smith who received the “Excellence in Advancing Pharmacogenomics Through Collaboration” award from American Society of Pharmacovigilance! The award honors leaders for driving #PGx advancements by fostering collaboration across disciplines/organizations/sectors. pharmacytimes.com/view/stripe-na…